GlobeNewswireNOV 32 min read$ZNTL

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc. ( Nasdaq: ZNTL ) , a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the ...

Original reporting

GlobeNewswire · ZENTALIS PHARMACEUTICALS

Published Nov 3, 2025, 1:15 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 3, 2025, 1:31 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences — source image — Source · www.globenewswire.com

Decision brief

The 30-second read

$ZNTLNeutralMed

Why it matters

Participation in investor conferences typically aims to boost visibility and attract investment, possibly leading to short-term price appreciation.

Market read

The news is relevant for investors interested in biotech and oncology sectors, with moderate impact expected on ZNTL stock.

What to watch

Potential delays or negative news from the conferences could lead to short-term declines.

Timing: High, as the events are upcoming and can influence short-term trading.

Background

Zentalis Pharmaceuticals is developing novel oncology therapeutics, with recent clinical progress and strategic partnerships.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ZNTLNeutralMedium confidence

Context

The news pertains directly to Zentalis Pharmaceuticals, a biotech company focused on oncology therapeutics.

Expected impact

Moderate upward price movement expected in the short term.

Evidence & confidence

Investor conferences often lead to increased visibility and potential positive developments, but no immediate news or catalysts are provided.

Market effects

Sector

Potential positive impact on biotech and life sciences sectors due to increased investor interest.

Regional

Limited regional impact, primarily affecting US-based biotech stocks.

Global

Minimal global market impact, specific to biotech sector.

Counterpoint

What could challenge this read

The conference participation may be a routine event with limited immediate impact, and the stock could remain range-bound.

Key entities

Company
Zentalis Pharmaceuticals
A clinical-stage biopharmaceutical company specializing in cancer therapeutics.

Read at source ← All news

AUG 14

$ZNTLHighAI 9/10

Why is Zentalis Pharmaceuticals stock tumbling today?

Zentalis Pharmaceuticals shares fell about 15% in pre-open trading after the company announced and priced a large underwritten public offering. The deal issues 23 million shares at $3.50 each, with an option for up to 3.45 million more. Gross proceeds are about $80.5 million to fund trials and research for azenosertib.

investing.com3 min

AUG 13

$ZNTLMedAI 8/10

Zentalis Pharmaceuticals stock falls on public offering news

Zentalis Pharmaceuticals (NASDAQ:ZNTL) shares fell about 6.5% in after-hours after it announced an underwritten public offering of common stock and pre-funded warrants. The company plans to use net proceeds plus existing cash for clinical trials, regulatory filings, manufacturing, and general corporate purposes. Joint bookrunners include TD Cowen, Guggenheim, and Oppenheimer.

investing.com4 min

AUG 6

$ZNTLMed

Zentalis Pharmaceuticals, Inc. (ZNTL): Results of Operations and Financial Condition

Zentalis Pharmaceuticals, Inc. (ZNTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates • Following U.S. regulatory discussions, accelerated approval strategy remains intact, supported by DENALI Part 2 • Enrollment completed in Part 2a and 2b of the DENALI trial;

SEC EDGAR 8-K6 min

JUL 17

$MANMedAI 8/10

ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Movin

ManpowerGroup reported upbeat Q2 results. Adjusted earnings were 99 cents per share, above analysts’ 95 cents estimate. Revenue increased 8% year over year to $4.86 billion, or 6% in constant currency, versus $4.72 billion expected. ManpowerGroup shares rose 5.8% to $54.63 on Friday.

benzinga.com2 min

SEP 27

$SNPSHigh

Is Synopsys (SNPS) a Breakout Play as Headwinds Subside and BNP Paribas Upgrades?

BNP Paribas upgraded Synopsys (SNPS) to Neutral with a $420 price target, citing easing headwinds and AI integration. SNPS reported Q3 revenue of $2.477B, up from $1.740B a year earlier, and raised its fiscal 2026 revenue outlook to ~$9.715B. The Ansys acquisition is expected to drive growth and synergies, though risks include integration challenges and China's demand.

insidermonkey.com3 min